

Journal of Hepatology CTAT methods

Tables for a “Complete, Transparent, Accurate and Timely account” (CTAT) are now mandatory for all revised submissions. The aim is to enhance the reproducibility of methods.

- Only include the parts relevant to your study
- Refer to the CTAT in the main text as ‘Supplementary CTAT Table’
- Do not add subheadings
- Add as many rows as needed to include all information
- Only include one item per row

If the CTAT form is not relevant to your study, please outline the reasons why:

N/A

1.1 Antibodies

Name	Citation	Supplier	Cat no.	Clone no.
N/A				

1.2 Cell lines

Name	Citation	Supplier	Cat no.	Passage no.	Authentication test method
HepG2.2.15	RRID:CVCL_L855	Dr. B. Korba	N/A	< 50	Morphology, growth curve analysis
HepG2	RRID:CVCL_0027	ATCC	ATCC® HB-8065™	<50	Morphology, growth curve analysis
Huh7	RRID:CVCL_0336	Dr.T.Wakita	N/A	<50	Morphology, growth curve analysis
MT-2	RRID:CVCL_2631	NIH AIDS Reagent Program	237	<50	Morphology, growth curve analysis
MOLT-4	RRID:CVCL_0013	ATCC	ATCC® CRL-1582™	<50	Morphology, growth curve analysis
WiDr	RRID:CVCL_2760	JCRB	JCRB0224	15	DNA Profile (STR)

1.3 Organisms

Name	Citation	Supplier	Strain	Sex	Age	Overall number
PXB-mice	Tateno C, Kawase Y, Tobita Y, et al. Generation of Novel Chimeric Mice with Humanized Livers by Using Hemizygous cDNA-uPA/SCID Mice. <i>PLoS One</i> . 2015;10(11):e0142145.	PhoenixBio Co., Ltd.	cDNA-uPA ^{wild/+} /SCID	male	29-31 weeks	34

1.4 Sequence based reagents

Name	Sequence	Supplier

1.5 Biological samples

Description	Source	Identifier
PXB-cells	PhoenixBio Co., Ltd.	PPC-P96
Human primary hepatocyte	SCR ScienCell Research Laboratories	5200/9351

1.6 Deposited data

Name of repository	Identifier	Link
N/A		

1.7 Software

Software name	Manufacturer	Version
Maestro	Schrödinger, LLC, New York	version 10.7.015

1.8 Other (e.g. drugs, proteins, vectors etc.)

E-CFCP: (1 <i>S</i> ,3 <i>S</i> ,5 <i>S</i> , <i>E</i>)-3-(2-amino-6-oxo-1,6-dihydro-9 <i>H</i> -purin-9-yl)-2-(fluoromethylene)-5-hydroxy-1-(hydroxymethyl)cyclopentane-1-carbonitrile	Z-CFCP: (1 <i>S</i> ,3 <i>S</i> ,5 <i>S</i> , <i>Z</i>)-3-(2-amino-6-oxo-1,6-dihydro-9 <i>H</i> -purin-9-yl)-2-(fluoromethylene)-5-hydroxy-1-(hydroxymethyl)cyclopentane-1-carbonitrile	CMCdG: 4'-Cyano-methylenecarbocyclic-2'-deoxyguanosine
ETV: entecavir	TAF: tenofovir alafenamide	TDF: tenofovir disoproxil fumarate
3TC: lamivudine	ddC : 2',3'-Dideoxycytidine	GLS4: Morphothiadin
pHBV_{WT}^{C2}	pHBV_{ADV-R}^{A181T/N236T}	pHBV_{ETV-R}^{L180M/S202G/M204V}
HIV-1_{LAI}	poly I:C	IFN-α : interferon- α
IL-2: interleukin-2		

1.9 Please provide the details of the corresponding methods author for the manuscript:

<p>Hiroaki Mitsuya</p> <p>1) Experimental Retrovirology Section HIV and AIDS Malignancy Branch National Cancer Institute, NIH, Bethesda, MD 20892, USA Phone: +1-240-858-3260 Email: hiroaki.mitsuya2@nih.gov</p> <p>2) Department of Refractory Viral Infections, National Center for Global Health & Medicine Research Institute, 1-21-1 Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan</p>

Phone: +81-33-202-7181
Fax: +81-33-202-7364
Email: hmitsuya@hosp.ncgm.go.jp

2.0 Please confirm for randomised controlled trials all versions of the clinical protocol are included in the submission. These will be published online as supplementary information.

N/A